Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.

We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.